New Delhi, Aug 3 (PTI) GlaxoSmithKline Pharmaceuticals Ltd on Tuesday reported a 30.44 per cent rise in consolidated net profit to Rs 335.88 crore in the September quarter, driven by strong growth in sales across verticals.
The pharma company had posted a net profit of Rs 257.49 crore in the year-ago period, said a regulatory filing.
The company's total income rose to Rs 1,256.35 crore during the second quarter of the ongoing fiscal, compared to Rs 1,013.51 crore a year earlier, it said.
Total expenses increased to Rs 797 crore in Q2 FY27 from Rs 662.15 crore a year ago, the filing said.
During the April-September period in FY27, the company's net profit rose nearly 24 per cent to Rs 573 crore from Rs 462.50 crore in the corresponding period of the previous financial year.
The company delivered strong growth across its general medicines, vaccines and speciality medicines portfolios, reflecting the continued evolution of its innovation portfolio, underpinned by commercial excellence, GlaxoSmithKline Pharmaceuticals said in a release.
GSK India Managing Director Bhushan Akshikar said, "Our strong performance this quarter reflects the robust execution of our strategy to build a science-first, innovation-led business."
"In line with global priorities, we continue to accelerate our efforts on late-stage pipeline assets, build momentum for our key launches across oncology and adult vaccination, and simplify our ways of working. At the same time, amid a dynamic geopolitical environment that continues to drive inflationary pressures and supply chain risks, we stay focused on building resilience across our business," Akshikar added.
